Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.